PHE Analysis Demonstrates Efficacy of COVID Vaccines Against Delta Variant
Recent analysis has shown that two doses of COVID-19 vaccines are highly effective against hospitalization as a result of infection with the Delta variant of COVID-19.
Analysis by Public Health England (PHE) has shown that two doses of COVID-19 vaccines are highly effective against hospitalization as a result of infection with the Delta variant of COVID-19.
The real-world data, which were announced in a June 14, 2021 press release, have shown that two doses of the Pfizer-BioNTech vaccine are 96% effective at preventing hospitalization and two doses of the Oxford-AstraZeneca vaccine are 92% effective against hospitalization due to the Delta variant of COVID-19. These results are comparable with the efficacy found against hospitalization from the Alpha variant of the virus.
As of yet, the level of protection offered by the vaccines against mortality from the Delta variant is not known, but further work is underway to establish these data also. However, it is anticipated that the vaccines’ level of protection against mortality will also be high, as has been the case with other variants.
“These hugely important findings confirm that the vaccines offer significant protection against hospitalization from the Delta variant,” said Mary Ramsay, head of Immunisation at PHE, in the press release. “The vaccines are the most important tool we have against COVID-19. Thousands of lives have already been saved because of them.”
Source: PHE
